retatrutide clinical trials brazil Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Retatrutide FDA Approval Status 2026:

SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week Madison's Ozempic Journey Within the first week of starting, Madison noticed an immediate change

Inflammatory bowel diseases 2016;22:207897

Because Retatrutide remains an investigational compound, any mention of an 8mg figure online reflects research reporting rather than an approved prescribing standard

Combined with semaglutide in the BELIEVE trial (results published May 2026), the combination achieved substantial weight loss with about 92% of it coming from fat, and lean mass was largely preserved

In a landmark Phase 2 trial published in the New England Journal of Medicine, participants receiving the 12 mg dose experienced mean weight loss of 24.2% at 48 weeks, significantly exceeding results from earlier GLP-1 or dual-agonist therapies